1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Active Pharmaceutical Ingredients CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Active Pharmaceutical Ingredients CDMO Market, by API Type / Molecule Type
8.1.1. Small Molecule APIs
8.1.1.1. Market Revenue and Forecast
8.1.2. Biologic / Macromolecular APIs
8.1.2.1. Market Revenue and Forecast
8.1.3. Highly Potent APIs (HPAPIs)
8.1.3.1. Market Revenue and Forecast
8.1.4. Antibody-Drug Conjugate (ADC) Payloads
8.1.4.1. Market Revenue and Forecast
8.1.5. Others (e.g., peptides, oligonucleotides)
8.1.5.1. Market Revenue and Forecast
9.1. Active Pharmaceutical Ingredients CDMO Market, by Service / Workflow Stage
9.1.1. Process Development
9.1.1.1. Market Revenue and Forecast
9.1.2. Clinical Stage Manufacturing
9.1.2.1. Market Revenue and Forecast
9.1.3. Commercial Manufacturing
9.1.3.1. Market Revenue and Forecast
9.1.4. Analytical & Regulatory Support
9.1.4.1. Market Revenue and Forecast
10.1. Active Pharmaceutical Ingredients CDMO Market, by Therapeutic Application / End Use
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast
10.1.2. Immunology & Autoimmune Diseases
10.1.2.1. Market Revenue and Forecast
10.1.3. Cardiovascular Diseases
10.1.3.1. Market Revenue and Forecast
10.1.4. Infectious Diseases
10.1.4.1. Market Revenue and Forecast
10.1.5. Others (e.g. Neurology, Rare Diseases)
10.1.5.1. Market Revenue and Forecast
11.1. Active Pharmaceutical Ingredients CDMO Market, by Customer Type
11.1.1. Innovative / Big Pharma Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Biotechnology Firms
11.1.2.1. Market Revenue and Forecast
11.1.3. Generic Drug Manufacturers
11.1.3.1. Market Revenue and Forecast
11.1.4. Research Organizations / Academia
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by API Type / Molecule Type
12.1.2. Market Revenue and Forecast, by Service / Workflow Stage
12.1.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.1.4. Market Revenue and Forecast, by Customer Type
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by API Type / Molecule Type
12.1.5.2. Market Revenue and Forecast, by Service / Workflow Stage
12.1.5.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.1.5.4. Market Revenue and Forecast, by Customer Type
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by API Type / Molecule Type
12.1.6.2. Market Revenue and Forecast, by Service / Workflow Stage
12.1.6.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.1.6.4. Market Revenue and Forecast, by Customer Type
12.2. Europe
12.2.1. Market Revenue and Forecast, by API Type / Molecule Type
12.2.2. Market Revenue and Forecast, by Service / Workflow Stage
12.2.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.2.4. Market Revenue and Forecast, by Customer Type
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by API Type / Molecule Type
12.2.5.2. Market Revenue and Forecast, by Service / Workflow Stage
12.2.5.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.2.5.4. Market Revenue and Forecast, by Customer Type
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by API Type / Molecule Type
12.2.6.2. Market Revenue and Forecast, by Service / Workflow Stage
12.2.6.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.2.6.4. Market Revenue and Forecast, by Customer Type
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by API Type / Molecule Type
12.2.7.2. Market Revenue and Forecast, by Service / Workflow Stage
12.2.7.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.2.7.4. Market Revenue and Forecast, by Customer Type
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by API Type / Molecule Type
12.2.8.2. Market Revenue and Forecast, by Service / Workflow Stage
12.2.8.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.2.8.4. Market Revenue and Forecast, by Customer Type
12.3. APAC
12.3.1. Market Revenue and Forecast, by API Type / Molecule Type
12.3.2. Market Revenue and Forecast, by Service / Workflow Stage
12.3.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.3.4. Market Revenue and Forecast, by Customer Type
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by API Type / Molecule Type
12.3.5.2. Market Revenue and Forecast, by Service / Workflow Stage
12.3.5.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.3.5.4. Market Revenue and Forecast, by Customer Type
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by API Type / Molecule Type
12.3.6.2. Market Revenue and Forecast, by Service / Workflow Stage
12.3.6.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.3.6.4. Market Revenue and Forecast, by Customer Type
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by API Type / Molecule Type
12.3.7.2. Market Revenue and Forecast, by Service / Workflow Stage
12.3.7.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.3.7.4. Market Revenue and Forecast, by Customer Type
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by API Type / Molecule Type
12.3.8.2. Market Revenue and Forecast, by Service / Workflow Stage
12.3.8.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.3.8.4. Market Revenue and Forecast, by Customer Type
12.4. MEA
12.4.1. Market Revenue and Forecast, by API Type / Molecule Type
12.4.2. Market Revenue and Forecast, by Service / Workflow Stage
12.4.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.4.4. Market Revenue and Forecast, by Customer Type
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by API Type / Molecule Type
12.4.5.2. Market Revenue and Forecast, by Service / Workflow Stage
12.4.5.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.4.5.4. Market Revenue and Forecast, by Customer Type
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by API Type / Molecule Type
12.4.6.2. Market Revenue and Forecast, by Service / Workflow Stage
12.4.6.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.4.6.4. Market Revenue and Forecast, by Customer Type
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by API Type / Molecule Type
12.4.7.2. Market Revenue and Forecast, by Service / Workflow Stage
12.4.7.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.4.7.4. Market Revenue and Forecast, by Customer Type
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by API Type / Molecule Type
12.4.8.2. Market Revenue and Forecast, by Service / Workflow Stage
12.4.8.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.4.8.4. Market Revenue and Forecast, by Customer Type
12.5. Latin America
12.5.1. Market Revenue and Forecast, by API Type / Molecule Type
12.5.2. Market Revenue and Forecast, by Service / Workflow Stage
12.5.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.5.4. Market Revenue and Forecast, by Customer Type
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by API Type / Molecule Type
12.5.5.2. Market Revenue and Forecast, by Service / Workflow Stage
12.5.5.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.5.5.4. Market Revenue and Forecast, by Customer Type
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by API Type / Molecule Type
12.5.6.2. Market Revenue and Forecast, by Service / Workflow Stage
12.5.6.3. Market Revenue and Forecast, by Therapeutic Application / End Use
12.5.6.4. Market Revenue and Forecast, by Customer Type
13.1. Neuland Laboratories
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Laurus Labs
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Apeloa Pharmaceutical
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Piramal Pharma Solutions
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Lonza
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Thermo Fisher Scientific
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Catalent, Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Abbott
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Abbott
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Abbott
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
